E-cadherin和N-cadherin在前列腺癌中的表达及意义

发布时间：2018-07-12 08:30

本文选题：E-cadherin + N-cadherin　；参考：《兰州大学》2014年硕士论文

【摘要】：目的：研究上皮型钙粘蛋白(E-cadherin)和神经元型钙粘蛋白(N-cadherin)在良性前列腺增生组织及前列腺癌组织中的表达情况,以探讨E-cadherin和N-cadherin在前列腺癌发生发展过程中的作用及意义。方法：采用免疫组织化学法(SP法)检测51例前列腺癌组织和47例良性前列腺增生组织中E-cadherin和N-cadherin的表达,根据半定量积分法判断阳性结果。根据前列腺癌的病理分化等级及临床分期,采用x2检验对E-cadherin、 N-cadherin与前列腺癌的关系进行统计分析。采用RT-PCR方法检测E-cadherin mRNA以及N-cadherin mRNA在前列腺增生和前列腺癌中的表达,并进行统计学分析。结果：1.在良性前列腺增生组织中,E-cadherin阳性表达率为87.23%,N-cadherin的阳性表达率为4.26%；在前列腺癌组织中,E-cadherin阳性表达率为31.37%, N-cadherin的阳性表达率为86.27%。与前列腺增生组织中的表达结果相比较,E-cadherin和N-cadherin在前列腺癌中的表达具有显著差异(P0.01)。2. E-cadherin在前列腺癌组织中的高分化组、中分化组以及低分化组的阳性表达率分别为75.00%、46.67%以及10.71%; N-cadherin在前列腺癌组织中的高分化组、中分化组以及低分化组的阳性表达率分别为37.5%、80.00%及96.43%。E-cadherin和N-cadherin在前列腺癌高、中、低分化组各组之间进行两两比较,均有差异(P0.05)。3. E-cadherin在前列腺癌临床分期A、B、C、D各期的阳性表达率分别为100.00%、75.00%、36.84%及4.55%, N-cadherin在前列腺癌临床分期A、B、C、D各期的阳性表达率分别为50.00%、37.50%、57.89%及86.36%。4. E-cadherin mRNA和N-cadherin mRNA的表达,在前列腺癌组织中的Gleason评分低分化组与前列腺增生组织相比较具有显著性差异(P0.01); Gleason评分中分化组与前列腺增生组相比较具有统计学意义(P0.05)；而Gleason评分高分化组与前列腺增生组相比较无显著性差异。结论：1. E-cadherin与前列腺癌的恶性程度及临床分期呈负相关。2.N-cadherin与前列腺癌的恶性程度及临床分期呈正相关。
[Abstract]:Objective: to investigate the expression of E-cadherin and N-cadherin in benign prostatic hyperplasia (BPH) and prostate cancer, and to explore the role and significance of E-cadherin and N-cadherin in the development of prostate cancer. Methods: the expression of E-cadherin and N-cadherin in 51 cases of prostate cancer and 47 cases of benign prostatic hyperplasia were detected by immunohistochemical method (SP method). The relationship between E-cadherin, N-cadherin and prostate cancer was statistically analyzed by using x2 test according to the grade of pathological differentiation and clinical stage of prostate cancer. The expression of E-cadherin mRNA and N-cadherin mRNA in prostatic hyperplasia and prostate cancer were detected by RT-PCR. The result is 1: 1. The positive expression rate of E-cadherin was 4.26 in benign prostatic hyperplasia, 31.37 in prostate cancer and 86.27 in N-cadherin. The expression of E-cadherin and N-cadherin in prostate cancer was significantly different from that in benign prostatic hyperplasia (P0.01). The positive expression rates of E-cadherin in prostate cancer tissues were 75.00%, 46.67% and 10.71%, respectively, and the positive rates of N-cadherin in prostate cancer tissues were 75.00% and 10.71%, respectively. The positive expression rates of E-cadherin and N-cadherin in moderately differentiated group and poorly differentiated group were 37.50.000% and 96.43km. E-cadherin and N-cadherin were significantly higher than those in poorly differentiated group (P0.05). The positive expression rate of E-cadherin in clinical stage of prostate cancer was 100.000.The positive rate of N-cadherin in clinical stage of prostate cancer was 50.0057.50% and 86.360.45%, respectively. The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4.The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4.The positive expression rate of E-cadherin in clinical stage of prostate cancer was 57.89% and 86.36.4. The expression of E-cadherin mRNA and N-cadherin mRNA in prostate cancer was significantly higher than that in prostatic hyperplasia (P0.01), and there was significant difference in Gleason score between differentiated group and prostatic hyperplasia group (P0.05). There was no significant difference in Gleason score between high differentiation group and benign prostatic hyperplasia group. Conclusion 1. E-cadherin was negatively correlated with the malignant degree and clinical stage of prostate cancer. 2.N-cadherin was positively correlated with the malignant degree and clinical stage of prostate cancer.
【学位授予单位】：兰州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25

【参考文献】